Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
Mirum Pharmaceuticals (MIRM) Stock Price & Analysis
623 Followers
MIRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$23.14 - $35.56
Previous Close$33.88
Volume200.46K
Average Volume (3M)651.23K
Market Cap
$1.60B
Enterprise Value$1.62B
Total Cash (Recent Filing)$286.33M
Total Debt (Recent Filing)$308.14M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 01, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.77
Shares Outstanding47,133,021
10 Day Avg. Volume1,327,556
30 Day Avg. Volume651,234
Standard Deviation0.35
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-355.02
Price to Sales (P/S)21.72
Price to Cash Flow (P/CF)-22.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.05
Enterprise Value/Gross Profit11.62
Enterprise Value/Ebitda-13.03
Forecast
1Y Price Target
$55.20Price Target Upside62.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Mirum Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessVolixibat demonstrated unprecedented reductions in pruritis in the Phase 2 VANTAGE study in PBC, opening the door for a competitive profile in PBC and a clear road to approval in PSC.
Drug ApprovalMirum completes its NDA submission for chenodiol for CTX with a likely approval potentially providing an inflection point in revenue for the bile acid drug.
Market OpportunityOrphan Drug designation would provide seven years of exclusivity, and MIRM would be allowed to promote the drug, which would improve diagnosis rates.
Bears Say
Competitive PositionConcerns from experts about volixibat's position in the PBC treatment market due to competitive intensity highlight forecasted challenges.
RevenueLivmarli revenue of $42.8mm was below/in line with our/consensus of $51.2mm/$43.0mm.
SalesUS sales were down due to the disruption in claims processing post the Change Healthcare cyberattack.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $35.56 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Aug 01, 2024 which is in 26 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on May 08, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.12.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$0.47.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 47,133,022 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 3.155%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Ardsley Advisory Partners. It holds Mirum Pharmaceuticals Inc’s shares valued at 6M.
---
Mirum Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.20 (62.40% Upside)
$55.20 (62.40% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 87%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 535.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $128.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.08%
12-Months-Change
Fundamentals
Return on Equity
-83.06%
Trailing 12-Months
Asset Growth
95.47%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Earnings Call
Q1 2024
0:00 / 0:00
---
MIRM Stock 12 Month Forecast
Average Price Target
$55.20
▲(62.40% Upside)
Technical Analysis
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
27/30 ratings generated profit
1 Year Average Return
+25.91%
reiterated a buy rating 18 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +25.91% per trade.
---